智通财经APP讯，高视医疗(02407)发布公告，于近日，本公司全资附属公司 Teleon Surgical B.V.达成由医疗器械指令(MDD)过渡至医疗器械法规(MDR)的重要里程碑，其自研亲水性丙烯酸人工晶状体(IOL)产品组合获得指定验证机构的MDR CE认证。
获得此项认证是本公司自研亲水性材料为基础的整个产品组合，全部取得 MDR CE认证的重要迈进，有利于成本的进一步降低和塬材料的长期保障，亦证明了本公司整个团队的奉献精神、专业知识与不懈努力。
亲水性丙烯酸LENTIS®、FEMTIS®及VISIOTIS®系列产品，采用先进的分区透镜设计，为外科医师及病患提供显著优势。此创新设计借由最佳化光线分布、提供屈光稳定性及改善对比视力以提升视觉效果。此外，亲水性丙烯酸材料可确保极佳的生物相容性，让病患长期感到满意。
凭藉上述里程碑达成及认证获得，本公司得以将创新技术及产品带给欧洲及全球市场的更多患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.